Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058429 | 1.00 | KMT2A (0.38) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30608409 | 1.00 | KMT2A (0.38) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14572918 | 1.00 | KMT2A (0.38) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2058915 | 0.79 | ALDH1A1 (0.46) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL2058978 | 0.79 | ALDH1A1 (0.46) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL12589591 | 0.79 | ALDH1A1 (0.32) | KDM4EALDH1A1 | |
| SCHEMBL2058977 | 0.79 | ALDH1A1 (0.46) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL26118933 | 0.79 | ALDH1A1 (0.46) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL11358106 | 0.77 | KMT2A (0.42) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7319816 | 0.76 | KMT2A (0.36) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968605-B2 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. (PT) | 2011-06-28 | — | — | US | disclosed |
| EP-2099439-A2 | METHODS FOR TREATING INFLAMMATORY DISEASE BY ADMINISTERING ALDEHYDES AND DERIVATIVES THEREOF | ALFAMA - INVESTIGAÇÃO E DESENVOLVIMENTO DE PRODUTO (PT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008069688-A2 | METHODS FOR TREATING INFLAMMATORY DISEASE BY ADMINISTERING ALDEHYDES AND DERIVATIVES THEREOF | ALFAMA - INVESTIGAÇÃO E DESENVOLVIMENTO DE PRODUTOS FARMACÊUTICOS LDA (PT) | 2008-06-12 | — | — | WO | disclosed |
| US-20080026984-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUCTOS FARMACEUTICOS LDA (PT) | 2008-01-31 | — | — | US | disclosed |
| US-20070219120-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUCTOS FARMACEUTICOS LDA (PT) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080026984-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | MPO, TNF, AOX1 | KMT2A 3726/4885CHRNB2 3627/4885CHRNA4 4082/4885 |
| US-20070219120-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | MPO, TNF, AOX1 | KMT2A 3726/4885CHRNB2 3627/4885CHRNA4 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.